All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

glutamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1310	56-86-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: glutamate glutamic acid L-Glutamic acid glutaminic acid glutaminol glutamic acid hydrochloride glutamic acid HCl	A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM. Molecular weight: 147.13 Formula: C5H9NO4 CLOGP: -2.69 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 100.62 ALOGS: -0.26 ROTB: 4

Drug dosage:

Dose	Unit	Route
1.50	g	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	582.58 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	71.91	64.47	19	249	21627	34935036

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A09AB01	ALIMENTARY TRACT AND METABOLISM DIGESTIVES, INCL. ENZYMES DIGESTIVES, INCL. ENZYMES Acid preparations
CHEBI has role	CHEBI:78675	fundamental metabolites
CHEBI has role	CHEBI:25512	neurotransmitters
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:173085	ferroptosis inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.97	acidic
pKa2	3.6	acidic
pKa3	10.35	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		IC50	6.21		CHEMBL
Glutathione reductase, mitochondrial	Enzyme	P00390	GSHR_HUMAN		Ki	4.37		CHEMBL
Glutamate receptor 1	Ion channel	P42261	GRIA1_HUMAN		Ki	5.87		CHEMBL
Glutamate receptor ionotropic, kainate 1	Ion channel	P39086	GRIK1_HUMAN		Ki	6.15		CHEMBL
Glutamate receptor 2	Ion channel	P42262	GRIA2_HUMAN		Ki	6.03		CHEMBL
Metabotropic glutamate receptor 1	GPCR	Q13255	GRM1_HUMAN		Ki	6.60		CHEMBL
Glutamate dehydrogenase 1, mitochondrial	Enzyme	P00367	DHE3_HUMAN					WOMBAT-PK
Glutamate dehydrogenase 2, mitochondrial	Enzyme	P49448	DHE4_HUMAN					WOMBAT-PK
Glutamate receptor ionotropic, kainate 5	Ion channel	Q16478	GRIK5_HUMAN		Ki	6.15		CHEMBL
Metabotropic glutamate receptor 5	GPCR	P41594	GRM5_HUMAN		Ki	6.41		CHEMBL
Metabotropic glutamate receptor 4	GPCR	Q14833	GRM4_HUMAN		Ki	5.85		CHEMBL
Glutamate receptor 4	Ion channel	P48058	GRIA4_HUMAN		Ki	6.06		CHEMBL
Glutamate receptor ionotropic, kainate 2	Ion channel	Q13002	GRIK2_HUMAN		Ki	5.96		CHEMBL
Glutamate receptor ionotropic, kainate 3	Ion channel	Q13003	GRIK3_HUMAN		Ki	6.10		CHEMBL
Metabotropic glutamate receptor 7	GPCR	Q14831	GRM7_HUMAN		EC50	5.93		CHEMBL
Metabotropic glutamate receptor 6	GPCR	O15303	GRM6_HUMAN		EC50	5.31		CHEMBL
Metabotropic glutamate receptor 2	GPCR	Q14416	GRM2_HUMAN		EC50	6.54		CHEMBL
Excitatory amino acid transporter 1	Transporter	P43003	EAA1_HUMAN		Ki	4.46		CHEMBL
Excitatory amino acid transporter 2	Transporter	P43004	EAA2_HUMAN		Ki	4.21		CHEMBL
Excitatory amino acid transporter 3	Transporter	P43005	EAA3_HUMAN		Ki	7.29		CHEMBL
Glutamate receptor 3	Ion channel	P42263	GRIA3_HUMAN		Ki	6.60		PDSP
Glutamate receptor ionotropic, kainate 4	Ion channel	Q16099	GRIK4_HUMAN		Ki	7.74		PDSP
Metabotropic glutamate receptor 3	GPCR	Q14832	GRM3_HUMAN	AGONIST	Ki	7.40		IUPHAR
Metabotropic glutamate receptor 8	GPCR	O00222	GRM8_HUMAN	AGONIST	IC50	5.70		IUPHAR
Glutamate receptor 2	Ion channel		GRIA2_RAT		Ki	6.55		CHEMBL
Glutamate receptor ionotropic, NMDA 1	Ion channel		NMDZ1_RAT		EC50	5.54		CHEMBL
Glutamate receptor ionotropic, kainate 2	Ion channel		GRIK2_RAT		Ki	5.48		CHEMBL
Glutamate receptor ionotropic, kainate 1	Ion channel		GRIK1_RAT		Ki	6.85		CHEMBL
Metabotropic glutamate receptor 4	GPCR		GRM4_RAT		EC50	4.92		CHEMBL
Metabotropic glutamate receptor 6	GPCR		GRM6_RAT		EC50	4.80		CHEMBL
Glutamate receptor 1	Ion channel		GRIA1_RAT		EC50	4.46		CHEMBL
Glutamate receptor 3	Ion channel		GRIA3_RAT		EC50	4		CHEMBL
Glutamate receptor 4	Ion channel		GRIA4_RAT		EC50	4.77		CHEMBL
Glutamate receptor ionotropic, kainate 3	Ion channel		GRIK3_RAT		Ki	6.31		CHEMBL
Glutamate racemase	Enzyme		MURI_LACFE		Ki	4.55		CHEMBL
Metabotropic glutamate receptor 8	GPCR		GRM8_RAT		Ki	5.47		CHEMBL
Metabotropic glutamate receptor 8	GPCR		GRM8_MOUSE		EC50	7.66		CHEMBL
Metabotropic glutamate receptor 5	GPCR		GRM5_RAT		EC50	5.36		CHEMBL
Metabotropic glutamate receptor 1	GPCR		GRM1_RAT		EC50	5		CHEMBL
Metabotropic glutamate receptor 2	GPCR		GRM2_RAT		EC50	5.40		CHEMBL
Metabotropic glutamate receptor 3	GPCR		GRM3_RAT		EC50	5.52		CHEMBL
Glutamate racemase	Enzyme		MURI_HELPY		Ki	5.24		CHEMBL
Excitatory amino acid transporter 4	Transporter		EAA4_RAT		IC50	4.89		CHEMBL

External reference:

ID	Source
D00007	KEGG_DRUG
138-15-8	SECONDARY_CAS_RN
4018681	VANDF
C0061472	UMLSCUI
CHEBI:16015	CHEBI
GLU	PDB_CHEM_ID
CHEMBL76232	ChEMBL_ID
CHEMBL575060	ChEMBL_ID
DB00142	DRUGBANK_ID
CHEMBL1255943	ChEMBL_ID
D018698	MESH_DESCRIPTOR_UI
33032	PUBCHEM_CID
66	INN_ID
1369	IUPHAR_LIGAND_ID
3KX376GY7L	UNII
25916	RXNORM
4788	MMSL
4823	MMSL
7086	MMSL
NOCODE	MMSL
d00487	MMSL
001113	NDDF
008075	NDDF
010581	NDDF
38909000	SNOMEDCT_US
42271003	SNOMEDCT_US
85214009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.50 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.50 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	0.50 g	INTRAVENOUS	NDA	23 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	749 mg	INTRAVENOUS	ANDA	20 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	0.50 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.30 g	INTRAVENOUS	NDA	23 sections
ProSol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0499	INJECTION, SOLUTION	1.02 g	INTRAVENOUS	NDA	21 sections
ProSol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0499	INJECTION, SOLUTION	1.02 g	INTRAVENOUS	NDA	21 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	749 mg	INTRAVENOUS	ANDA	18 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	749 mg	INTRAVENOUS	ANDA	18 sections
Clinisol	HUMAN PRESCRIPTION DRUG LABEL	17	0338-0502	INJECTION, SOLUTION	749 mg	INTRAVENOUS	ANDA	18 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1130	INJECTION, SOLUTION	0.50 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1130	INJECTION, SOLUTION	0.50 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1130	INJECTION, SOLUTION	0.50 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1131	INJECTION, SOLUTION	0.30 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1131	INJECTION, SOLUTION	0.30 g	INTRAVENOUS	ANDA	15 sections
Premasol - sulfite-free (Amino Acid)	HUMAN PRESCRIPTION DRUG LABEL	19	0338-1131	INJECTION, SOLUTION	0.30 g	INTRAVENOUS	ANDA	15 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0409-4178	INJECTION, SOLUTION	576 mg	INTRAVENOUS	NDA	14 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0409-7171	INJECTION, SOLUTION	1107 mg	INTRAVENOUS	NDA	19 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0409-7172	INJECTION, SOLUTION	738 mg	INTRAVENOUS	NDA	19 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4178	INJECTION, SOLUTION	576 mg	INTRAVENOUS	NDA	13 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4178	INJECTION, SOLUTION	576 mg	INTRAVENOUS	NDA	13 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4179	INJECTION, SOLUTION	820 mg	INTRAVENOUS	NDA	14 sections
Aminosyn-PF	HUMAN PRESCRIPTION DRUG LABEL	18	0990-4179	INJECTION, SOLUTION	820 mg	INTRAVENOUS	NDA	14 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0990-7171	INJECTION, SOLUTION	1107 mg	INTRAVENOUS	NDA	19 sections
Aminosyn II	HUMAN PRESCRIPTION DRUG LABEL	17	0990-7171	INJECTION, SOLUTION	1107 mg	INTRAVENOUS	NDA	19 sections